Status:
COMPLETED
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants....
Eligibility Criteria
Inclusion
- Baseline health is stable.
- Has a clinical diagnosis of chronic HCV infection.
Exclusion
- Has a history of stroke or chronic seizures.
- Has a history of cancer.
- Has a history of human immunodeficiency virus (HIV) infection.
- Has had major surgery, donated blood or participated in another investigational study within the past 3 months.
Key Trial Info
Start Date :
February 23 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2012
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT00998985
Start Date
February 23 2010
End Date
November 8 2012
Last Update
July 17 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.